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Anti-Hexokinase 1 Antibody as 
a Novel serum Biomarker of a 
Subgroup of Diabetic Macular 
Edema
Tatsuya Yoshitake1, tomoaki Murakami1, shin Yoshitake1, Kiyoshi suzuma1, Yoko Dodo1, 
Masahiro Fujimoto1, shinji Ito2 & Akitaka tsujikawa1
Diabetic retinopathy (DR) induces the breakdown of the blood-retinal barrier and promotes 
neuroinflammation, although autoimmune responses to sequestered retinal antigens remain poorly 
understood. In this study, we investigated the autoantibodies for retinal antigens in sera from diabetic 
macular edema (DME) patients. Screening by immunoblotting demonstrated that IgG from 7 of 10 
DME sera samples reacted to an ~102-kDa autoantigen from porcine retinas. Immunoprecipitation with 
autoantibodies from DME sera and subsequent mass spectrometry enabled us to identify hexokinase 
1 as an autoantigen reactive to IgG from DME sera. IgG in 7 of 10 DME sera partially colocalized to 
hexokinase 1 in the outer plexiform layer of rodent retinas. Quantitative analyses using enzyme-linked 
immunosorbent assays revealed that the serum titers of this autoantibody were significantly higher in 
the DME sera than those in the sera from diabetic patients without DME, and 20 (24.1%) of the 83 DME 
serum samples had higher IgG titers than the cutoff value (mean + 2 standard deviations of the sera 
from diabetic patients without DR). Multivariate logistic regression analysis confirmed that the higher 
titer of anti-hexokinase 1 IgG was clinically feasible for the diagnosis of DME. These data identify anti-
hexokinase 1 antibody as a serum biomarker of a subset of DME.
Diabetic retinopathy (DR), a subset of diabetic microangiopathy, often leads to severe visual impairment world-
wide1–3. Diabetes promotes the breakdown of the blood-retinal barrier (BRB) and subsequently induces edema-
tous changes and dysfunction in neuroglial components in diabetic macular edema (DME)4. Recent advances in 
molecular biology and clinical trials have resulted in the clinical application of anti-vascular endothelial growth 
factor (VEGF) treatment for DME, which has had a significant impact on visual outcomes5–9. This result implies 
that better screening for or diagnosis of DME would improve the visual prognosis in diabetic patients.
Patients with diabetes mellitus (DM) routinely undergo blood sampling in the internal medicine clinic. 
Several blood biomarkers, e.g., fasting blood glucose and hemoglobin A1c (HbA1c), are used to monitor the 
clinical efficacy of systemic treatments or indicate the necessity of further examination for diabetic complica-
tions10,11. In particular, several serum biomarkers of DR are related to biochemical pathways, glucose metabolism, 
inflammation, microRNA, and the proteome12–17. Diabetic patients who visit the internal medicine clinic are not 
necessarily referred to the eye clinic and are not necessarily examined for vision-threatening DR1. These concerns 
suggest the necessity of identifying blood biomarkers of proliferative diabetic retinopathy (PDR) or DME that 
should be adequately treated by ophthalmologists.
Recent investigations have elucidated immunological aspects of chorioretinal vascular diseases18,19. The 
inner and outer BRBs, which are composed of retinal vascular endothelial cells and retinal pigment epithelium 
(RPE), respectively, sequester retinal autoantigens to prevent autoimmune disease development20–23. In chori-
oretinal vascular diseases, e.g., age-related macular degeneration (AMD) and DR, vascular hyperpermeabil-
ity or the disruption of properties of the RPE barrier allows immunological agents to react to the sequestered 
antigens. Autoantibodies against retinal antigens are subsequently induced, and innate immunity is activated 
in AMD19,24–26. In addition to their contribution to the pathogenesis of chorioretinal vascular diseases, these 
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antibodies indicate retinal impairment and can be biomarkers of these diseases24,25,27. Diabetes also modulates 
and is modulated by autoimmunity28, and several autoantibodies have been identified as serum biomarkers of 
diabetic complications29,30. However, antigens against autoantibodies from DME or PDR sera remain ill-defined.
In the current study, we identified anti-hexokinase 1 antibody as a novel serum autoantibody using a combi-
nation of biochemistry and mass spectrometry, and we investigated the association between the antibody titer 
and clinical parameters in DME.
Results
Screening of autoantibodies in DME sera. We first screened for anti-retinal autoantibodies in DME 
sera using immunoblotting for porcine total retinal lysates and found that 7 (70.0%) of the 10 DME sera samples 
showed immunoreactivity to an ~102-kDa antigen, whereas there were only minimal levels of band intensities 
reactive to DM sera (Fig. 1, Table 1). Additional immunofluorescence analysis using patients’ sera as primary 
antibodies revealed that 7 (70.0%) of the 10 DME sera exhibited immunoreactivity to autoantigens in the outer 
plexiform layer (OPL) of C57BL/6 J mice (data not shown).
Identification of hexokinase 1 as a target of DME autoantibodies. To identify the antigens reactive 
to the autoantibodies, we performed immunoprecipitation using DME sera and analyzed the precipitated pro-
teins by subsequent mass spectrometry (Fig. 2a, Supplementary Table S1). The mass spectrometry revealed that 
the ~102-kDa precipitated antigen was hexokinase 1. We then confirmed that the precipitated protein was reac-
tive to a commercially available anti-hexokinase 1 antibody and that the same sera from DME patients showed 
immunoreactivity to recombinant hexokinase 1 protein (Fig. 2b,c). We thus identified anti-hexokinase 1 antibody 
as one of the autoantibodies from DME sera.
Hexokinase 1, one of four major isozymes, mediates glucose phosphorylation, the first step in the glucose 
metabolism pathway, and is ubiquitously expressed and localizes to the surface of the mitochondrial outer mem-
brane31. Polymerase chain reaction (PCR) analysis showed that hexokinase 1 mRNA was expressed in the human 
retinas (Fig. 2d). Immunofluorescence staining revealed that hexokinase 1 was highly localized to the OPL, the 
outer half of the inner nuclear layer (INL), and the photoreceptor inner segment (IS) and, to a lesser extent, to 
the nerve fiber layer (NFL) and the inner plexiform layer (IPL) in human retinas (Fig. 2e). The mRNA levels and 
the protein localization were similar in the retinas of C57BL/6 J and Ins2Akita mice (Supplementary Fig. S1)32. 
The immunoreactivity of IgG from DME serum with high titers of anti-hexokinase 1 antibody was often colo-
calized with hexokinase 1 in the OPL and to some extent in the IPL of the mouse retinas (Fig. 3, Supplemenatary 
Table S2).
Figure 1. Immunoreactivity of DME sera to retinal lysates. Immunoblotting was performed to determine the 
immunoreactivity of serum IgG in 10 serum samples from the DM group (a) or DME group (b) to porcine 
retinal antigens. The patients’ characteristics are shown in Table 1.
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Quantitative analyses of serum titers of anti-hexokinase 1 antibody. Quantitative investigation 
using enzyme-linked immunosorbent assay (ELISA) revealed that the titer of anti-hexokinase 1 antibody in 
sera from patients with center-involved DME defined by optical coherence tomography (OCT) measurement 
(the DME group) was significantly higher than in nondiabetic subjects (the no DM group), patients with type 2 
DM but not DR (the DM group), or patients with DR but not center-involved DME (the DR group) (P = 0.002, 
P = 0.003, or P = 0.022, respectively; Fig. 4a, Table 2, Supplementary Fig. S2, Table S3). Twenty (24.1%) of the 83 
DME sera samples had higher titers of this autoantibody than the threshold of 2 standard deviation (SD) above 
the mean value in the DM group. We investigated 83 eyes with DME and found that the titers of this autoanti-
body were not related to the logarithm of the minimum angle of resolution visual acuity (logMAR VA) or central 
subfield (CSF) thickness (Fig. 4b,c). Additional analyses showed a trend toward higher titers in participants with 
moderate nonproliferative diabetic retinopathy (NPDR) or more severe grades, and the autoantibody titer in 
patients with severe NPDR was higher than in diabetic patients without DR (Fig. 4d, Supplemenatary Table S4). 
However, there were no significant differences between individual severity grades in the eyes in the DR group 
(Fig. 4e). The titer was correlated to the age of participants (ρ = 0.199, P = 0.004), whereas there were no associa-






Age (years) 60.8 ± 12.0 69.2 ± 5.9
Gender (male/female) 6/4 6/4
Diabetes duration (years) 8.8 ± 7.3 14.3 ± 8.0
Mean arterial blood pressure (mmHg) 92.2 ± 3.8 98.2 ± 13.1
HbA1c (%) 8.09 ± 1.44 7.39 ± 1.62
Systemic hypertension 7 8
Dyslipidemia 6 5
Phakic in both eyes 9 8
International classification
No apparent retinopathy 10 —
Mild NPDR — 0
Moderate NPDR — 5
Severe NPDR — 3
PDR — 2
Prior PRP in either eye — 4
Table 1. Characteristics of patients whose sera were analyzed by Western blotting.
Figure 2. Identification of anti-hexokinase 1 antibody as an autoantibody in DME serum. (a) Retinal 
autoantigens immunoprecipitated with serum IgG of the DM group or DME group were analyzed by SDS-
PAGE and silver staining. Subsequent mass spectrometry revealed that the ~102-kDa unique band (arrow 
in panel a) corresponded to hexokinase 1, which was confirmed by immunoblotting with rabbit monoclonal 
anti-hexokinase 1 antibody (b). The patients’ characteristics are shown in Supplementary Table S1. (c) Human 
recombinant hexokinase 1 was immunoblotted with IgG from DM or DME serum. (d) PCR analysis to 
determine the expression of hexokinase 1 mRNA in human retinas. (e) High levels of hexokinase 1 expression 
in the OPL, the outer half of the INL, and IS and, to a lesser extent, in the NFL and IPL in human retinas. Scale 
bar, 50 μm. GCL, ganglion cell layer; HK1, hexokinase 1; INL, inner nuclear layer; IPL, inner plexiform layer; IS, 
inner segment; NFL, nerve fiber layer; ONL, outer nuclear layer; OPL, outer plexiform layer; OS, outer segment.
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We recently identified anti-fumarase IgG in the sera from a subgroup of DME patients and therefore investi-
gated the relationship between these autoantibodies33. There was a moderate correlation between the serum titers 
of anti-hexokinase 1 IgG and anti-fumarase IgG in 83 cases of the DME group (ρ = 0.341, P = 0.002). Multivariate 
logistic regression analysis using systemic factors demonstrated that the serum titers of anti-hexokinase 1 IgG 
and anti-fumarase IgG were the significant predictors of center-involved DME in all 209 cases of type 2 DM or 
163 cases with DR (Tables 3, 4). By contrast, the areas under the receiver operating characteristic (ROC) curve 
(AROC) for DME cases of the serum titer of anti-hexokinase 1 IgG was 0.651 (95% confidence interval [CI], 
0.546–0.710) or 0.632 (95% CI, 0.546–0.717) in patients with diabetes or DR, respectively (Fig. 5a,b).
Discussion
In the current study, we identified anti-hexokinase 1 antibody as a novel autoantibody in sera from a subgroup 
of DME patients. In the screening of anti-retinal antibodies using Western blot analysis, IgG in most DME sera 
reacted to several autoantigens. Immunoprecipitation and subsequent peptide mass fingerprinting revealed one 
of the autoantigens to be hexokinase 1, which is expressed in the outer mitochondrial membrane in many cell 
types31. Hexokinase 1 is highly expressed in the OPL and the outer half of the INL in the human and rodent model 
retinas. Since these layers are composed of several cell types, e.g., bipolar cells, Müller cells, horizontal cells, and 
vascular cells, we could not determine its subcellular localization in specific cell types. Immunostaining demon-
strated that IgG from DME sera often showed fluorescence signals in the OPL and was partially colocalized with 
hexokinase 132. Quantitative analyses using ELISA revealed that the titer of anti-hexokinase 1 IgG was high in the 
subgroup of DME cases but not in PDR cases, suggesting the diagnostic significance of this autoantibody.
Serum biomarkers of diabetic complications would have clinical feasibility in the internal medicine clinic, 
where blood sampling is routinely performed. We thus employed statistical analysis to validate the signifi-
cance in the diagnosis or screening of center-involved DME. Multivariate analysis identified a higher titer of 
anti-hexokinase 1 IgG as a predictor of center-involved DME in diabetic patients, suggesting diagnostic signif-
icance, as in the case of anti-fumarase IgG33. However, 63 patients (75.9%) with DME had lower titers than the 
threshold, and the sensitivity was not high, which is consistent with low accuracy in the prediction of DME in 
the AROC analysis. These results mean that this autoantibody was not suitable for the screening of DME. Since 
Western blot demonstrated serum autoantibodies against several retinal antigens, further research to identify 
other autoantibodies may facilitate a composite diagnosis of higher quality.
The screening of anti-retinal antibodies using Western blot analysis revealed an autoantigen with an approx-
imate molecular weight of 102 kDa in 7 (70.0%) of the 10 sera samples from DME patients, although ELISA 
demonstrated that only 20 (24.9%) of the 83 DME serum samples contained titers of anti-hexokinase 1 antibody 
Figure 3. Localization of autoantigens from serum IgG with a high titer of anti-hexokinase 1 antibody. 
Immunofluorescence of serum IgG from representative cases of the DM and DME groups, which corresponded 
to the DM serum 4 and DME serum 10 in the Western blot experiements (Fig. 1), respectively (Supplementary 
Table S2). Fluorescence signals of serum IgG from DME patients were partially colocalized to hexokinase 1 in 
the OPL, IPL and IS of C57BL/6 J mice. Scale bar, 50 μm.
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above the cutoff value (mean + 2 SD). This discrepancy can be explained by other 100–110-kDa autoantigens in 
addition to hexokinase 1. Anti-retinal antibodies in the sera are induced in several diseases, e.g., cancer-associated 
retinopathy, melanoma-associated retinopathy, nonparaneoplastic autoimmune retinopathy (AIR), and 
AMD19,34–36. Because specific autoantigens with 100–110-kDa molecular weights have not been reported in these 
diseases, further investigation may reveal unknown autoantigens. Another possible explanation for the above-
mentioned discrepancy is that different epitopes were analyzed between sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and ELISA. ELISA maintains the three-dimensional conformation and therefore 
does not allow autoantibodies to recognize certain cryptic epitopes. By contrast, proteins with one-dimensional 
Figure 4. Quantification of the titer of anti-hexokinase 1 antibody in DME sera. (a) ELISA revealed that the titers 
of anti-hexokinase 1 IgG were higher in the DME group than in no DM group, DM group, or DR group. (b,c) In 
83 cases in the DME group, the titer of anti-hexokinase 1 antibody was not associated with either logMAR VA or 
CSF thickness. (d–f) The titer was associated with individual grades of DR severity in all diabetic cases (d), the DR 
group (e), and the DME group (f). The titers were not different between individual DR severity grades, although 
there was a trend toward higher titers in patients with moderate or severe NPDR in the DME group.
Characteristics







(n = 83) P-value
Age (years) 75.5 ± 7.70 63.5 ± 11.0* 62.7 ± 11.9* 64.1 ± 12.2* <0.001
Gender (male/female) 11/25 32/14* 58/22* 54/29* <0.001
Diabetes duration (years) — 11.3 ± 9.8 16.1 ± 9.6† 12.3 ± 8.2 0.009
Mean arterial blood pressure (mmHg) 87.8 ± 8.1 90.5 ± 7.4 93.8 ± 14.3 96.8 ± 11.7*† 0.001
HbA1c (%) — 7.76 ± 1.44 7.94 ± 1.59 7.85 ± 1.65 0.814
Systemic hypertension 21 25 52 55 0.515
Dyslipidemia 15 25 41 43 0.689
Phakic in both eyes 35 41 55*‡ 56*‡ <0.001
International classification
   No apparent retinopathy — 46 — —
   Mild NPDR — — 25 9
   Moderate NPDR — — 25 32
   Severe NPDR — — 16 21
   PDR — — 14 21
   Prior PRP in either eye — — 12 31 0.001
Table 2. Characteristics of the patients whose sera were quantified using ELISA. *P < 0.01 vs. no DM group; 
†P < 0.05 vs. DM group; ‡P < 0.01 vs. DM group.
6Scientific RepoRts |          (2019) 9:4806  | https://doi.org/10.1038/s41598-019-39777-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
amino acid sequences are separated under reducing and denaturing conditions in SDS-PAGE, which means that 
autoantibodies can react to cryptic epitopes, generally resulting in an immunoblot analysis with higher sensitivity.
It remains to be elucidated whether disrupted retinas induce autoantibodies or whether anti-retinal antibod-
ies promote retinal destruction. Although we have investigated the relationship of anti-hexokinase 1 antibody 
to systemic and ocular characteristics, we did not determine the mechanisms underlying the induction of this 
autoantibody. OCT investigations have demonstrated that a few patterns of pathomorphology and cystoid spaces 
often appear in the INL and OPL37. Because hexokinase 1 is highly expressed in the OPL, pathological cellular dis-
ruption in the OPL might promote the exposure of this intracellular protein into the extracellular spaces with sub-
sequent antigen recognition. In particular, BRB breakdown may allow retinal antigens to enter into the systemic 
circulation or let antigen-presenting cells, e.g., monocytes/macrophages, enter and exit the retinal parenchyma23. 
Subsequently, systemic B cells or plasma cells could produce antibodies against hexokinase 1.
Patients with DME but not PDR had higher titers of anti-hexokinase 1 antibody, whereas the titers were 
not as high in patients with PDR but not DME. In eyes with PDR, the main retinal lesions are the nonperfused 
areas, in which structural damage is observed in the NFL and ganglion cell layer38. We may speculate that this 
autoantibody is not elicited in PDR sera, because the protein amounts of hexokinase 1 are not high in these layers. 
Another possibility is that retinal antigens are lost in neurodegenerative processes within the nonperfused areas 
before the recognition of retinal autoantigens.
We further considered the molecular mechanisms underlying the loss of immune tolerance. The mRNA levels 
and location of hexokinase 1 expression did not differ between retinas from control and Ins2Akita C57BL/6 J 
mice, which suggests that changes in the levels or localization of gene expression did not influence the induc-
tion of this autoantibody. Instead, we hypothesize that posttranslational modifications, e.g., phosphorylation, 
glycation, and oxidation, can provide new epitopes and contribute to the loss of immune tolerance because high 
glucose often induces such modifications39–41. In addition, human leucocyte antigens (HLAs) are key molecules 
used for epitope presentation in antigen-presenting cells, e.g., dendritic cells and microglia/macrophages, and 
Characteristics
Univariate Multivariate
OR (CI 95%) P value OR (CI 95%) P value
Age 1.008 (0.985–1.032) 0.502 — —
Gender 1.343 (0.741–2.432) 0.331 — —
Diabetes duration 0.977 (0.946–1.010) 0.164 — —
Mean arterial blood pressure 1.029 (1.004–1.055) 0.024 1.031 (1.001–1.061) 0.039
HbA1c 0.987 (0.821–1.186) 0.885 — —
Systemic hypertension 1.250 (0.701–2.230) 0.450 — —
Dyslipidaemia 0.961 (0.551–1.675) 0.888 — —
Phakic in both eyes 1.543 (0.834–2.855) 0.167 — —
PDR in either eye 2.710 (1.288–5.702) 0.009 0.787 (0.273–2.266) 0.657
Prior PRP in either eye 5.663 (2.695–11.902) <0.001 8.011 (2.828–22.697) <0.001
Titer of anti-fumarase IgG 2077.4 (48.6–88862.3) <0.001 266.7 (3.0–23470.4) 0.014
Titer of anti-hexokinase 1 IgG 210.3 (16.5–2679.3) <0.001 183.8 (8.7–3889.9) <0.001
Table 3. Multivariate logistic regression analysis to determine the factors associated with center-involved 
DME in 209 diabetic patients. Univariate logistic regression or Multivariate logistic analysis using significant 
parameters (Wald’s chi-square > 2) as independent parameters.
Characteristics
Univariate Multivariate
OR (CI 95%) P value OR (CI 95%) P value
Age 1.010 (0.984–1.036) 0.452 — —
Gender 1.416 (0.727–2.758) 0.307 — —
Diabetes duration 0.953 (0.917–0.990) 0.014 0.936 (0.895–0.980) 0.005
Mean arterial blood pressure 1.018 (0.993–1.045) 0.164 — —
HbA1c 0.961 (0.788–1.172) 0.693 — —
Systemic hypertension 1.058 (0.554–2.019) 0.865 — —
Dyslipidaemia 0.996 (0.538–1.846) 0.991 — —
Phakic in both eyes 1.061 (0.549–2.050) 0.861 — —
PDR in either eye 1.597 (0.747–3.414) 0.227 — —
Prior PRP in either eye 3.378 (1.583–7.208) 0.002 7.224 (2.712–19.240) <0.001
Titer of anti-fumarase IgG 970.3 (15.4–61153.5) 0.001 143.5 (1.2–17185.2) 0.042
Titer of anti-hexokinase 1 IgG 100.1 (6.7–1507.3) <0.001 41.3 (1.8–941.3) 0.020
Table 4. Multivariate logistic regression analysis to determine the factors associated with center-involved 
DME in 163 DR participants. Univariate logistic regression or Multivariate logistic analysis using significant 
parameters (Wald’s chi-square > 2) as independent parameters.
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the heterogeneity of HLAs might explain why the titer is increased in the sera from a subgroup of but not in all 
DME patients. Another possibility is that diabetic complications other than DR may promote cellular damage and 
concomitant exposure to intracellular autoantigens and could be significantly related to DME.
We further considered the pathogenicity of anti-hexokinase 1 antibody. Because hexokinase 1 is highly 
expressed in the neuroglial components in the OPL, it is necessary to consider their neurotoxic effects32. With 
vascular hyperpermeability, smaller molecules enter the cytoplasm, which leads to edematous changes, includ-
ing intracytoplasmic swelling and liquefaction necrosis in Müller cells42. Neurotoxic factors in the plasma, e.g., 
thrombin and plasmin, also disrupt neuroglial components43. We speculated that such changes promote the 
extracellular exposure of intracellular hexokinase 1 and that anti-hexokinase 1 antibody might react to its anti-
gen and exacerbate neuroinflammation. Neutralizing antibodies generally block the function of their antigens, 
although it remains largely unknown whether this autoantibody in DME sera can inhibit the function of hexoki-
nase 1. HK1dea mice, in which the HK1 gene is ablated, suffer from deformation of the erythrocytes and anemia44. 
Further investigation should be pursued to determine whether anti-hexokinase 1 antibody is related to the rou-
leaux formation of red blood cells in DR or diabetic anemia.
There was a mild correlation between age and anti-hexokinase 1 antibody in this study. Anti-retinal anti-
bodies were increased in sera from AMD patients, and immunological changes associated with age remain to 
be investigated18,19. Although anti-hexokinase 1 antibody has not previously been reported as an autoantibody 
in AMD sera, cystoid spaces often develop in the OPL in AMD, and it remains to be investigated whether this 
autoantibody is increased in AMD sera. In sera from patients with paraneoplastic or nonparaneoplastic AIR, 
most autoantibodies react to retinal antigens in photoreceptor cells45. Because immunosuppressive treatment is 
effective for AIR, further clinical trials should be planned to elucidate whether immunosuppressive therapies, e.g., 
steroids, are effective for humoral immunity in DME.
This study had several limitations. The delayed fixation in the human samples cannot guarantee the correct 
localization and amount of mRNA levels. We therefore used the common mouse model of diabetes which was 
processed immediately after sacrifice to confirm the expression. These samples showed almost the same locali-
zation of hexokinase 1, although we could not completely reveal the gene expression in living retinas of diabetic 
patients. It had a small sample size and was retrospectively performed using sera from Japanese patients in a sin-
gle center. In the future, a prospective study with a larger cohort should be planned to validate the generalizability 
of the findings. Further experiments for epitope mapping should be planned, and the in vivo pathogenicity of this 
autoantibody should also be analyzed.
We identified anti-hexokinase 1 antibody in the sera from a subgroup of DME patients. Our data suggest that 
this autoantibody may serve as a novel serum biomarker of DME and for the diagnosis of DME in the internal 
medicine clinic.
Methods
Participants and biosampling. Participants were consecutively enrolled at the Department of 
Ophthalmology of Kyoto University Hospital from July 2014 to December 2015. We collected sera from nondia-
betic subjects (no DM group) and patients with type 2 DM who did not receive any treatment for macular lesions 
and divided diabetic patients into the following three groups: (1) the DM group, patients with type 2 diabetes 
but not DR; (2) the DR group, patients with DR but not center-involved DME; and (3) the DME group, patients 
with center-involved DME. The eligibility criteria included the following: (1) patients with type 2 DM and (2) the 
absence of treatment for macular lesions. The exclusion criteria included the following: (1) other chorioretinal 
diseases; (2) media opacity affecting fundus examination or OCT imaging; (3) history of intraocular surgery 
other than cataract surgery; (4) history of cataract surgery or panretinal photocoagulation (PRP) within one 
Figure 5. ROC curves for individual DR status of the titer of anti-hexokinase 1 antibody. The ROC curve for 
DME diagnosis of the titer of anti-hexokinase 1 IgG discriminating the DME group from no DME group in all 
209 cases encompassing the DM, DR, and DME groups (a) or the 163 cases encompassing the DR and DME 
groups (b).
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year; (5) history of anti-VEGF treatment; (6) any infection at sample collection; or (7) any history of autoimmune 
disease or malignancy. In the DR group, eyes that met the inclusion but not the exclusion criteria were evaluated 
according to the international clinical DR disease severity scale46. In the DME group, eyes with center-involved 
DME were evaluated47. If both eyes met the inclusion/exclusion criteria, we selected the eye with greater CSF 
thickness for analysis. Sera were processed and aliquoted within 1 hour after sampling and immediately stored at 
−80 °C. We avoided any freeze-thaw cycle before sample use.
This study was conducted in accordance with the Declaration of Helsinki after receiving approval from the 
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee (C845). The study was registered 
at the UMIN Japan Clinical Trial Registry (UMIN000014015). We obtained written informed consent after pro-
viding a full explanation of the nature of this study.
OCT. After comprehensive examination, best-corrected decimal VA was measured and converted to the log-
MAR VA. DME was objectively diagnosed by OCT-measured retinal thickness, as described previously47,48. 
Briefly, retinal sectional images in the macula were obtained using the raster scan mode of spectral-domain 
OCT (Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany). We quantified the mean retinal thickness 
in the CSF (within 1 mm) of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. Center-involved 
DME was diagnosed in eyes with a CSF thickness greater than 320 μm and 305 μm in male and female patients, 
respectively47.
Animals. Two- to three-month-old male mice (C57BL/6 J wild-type and Ins2Akita diabetic animals) were 
purchased from SLC Japan (Hamamatsu, Japan) and housed in accordance with the Institutional Animal Care and 
Use Committee guidelines as well as the Association Research in Vision and Ophthalmology (ARVO) Statement 
for Use of Animals in Ophthalmic and Vision Research. All protocols were approved by the Institutional Review 
Board of the Kyoto University Graduate School of Medicine (MedKyo 14564, MedKyo 15197, MedKyo 16102). 
Following anesthesia with a lethal dose of ketamine/xylazine, eyes were harvested and used for further experi-
ments, e.g., RNA purification and immunostaining.
PCR. RNA levels in the retinas were evaluated using PCR. Briefly, mouse retinas were harvested, fro-
zen in liquid nitrogen, and stored at −80 °C. RNA from the homogenized retinas was isolated using ice-cold 
Sepasol RNA I Super solution (Nacalai Tesque, Japan) and chloroform, followed by ethanol precipitation. The 
purified mRNA was applied to reverse transcription using SuperScript II (Life Technologies, Gaithersburg, 
MD) in order to obtain cDNA. Human retinal cDNA was purchased from ScienCell Research Laboratories 
(Carlsbad, CA). Human and mouse cDNA was amplified using Taq polymerase (Ex Taq; TaKaRa Bio, Otsu, 
Japan) as follows: 95 °C for 20 seconds, 56 °C for 20 seconds, and 72 °C for 30 seconds, for 35 cycles. Forward 
and revere primers (5′-GTTGGTGTCGACGGATCTCT-3′ and 5′-CGCATCCTCTTCTTCACCTC-3′, 
respectively) were used to determine the mRNA expression of human hexokinase 1 (accession number: 
NM_000188) in the retinas. Similarly, mouse cDNA was applied to PCR using forward and reverse primers 
(5′-AGTGGAAGCCAGCTTTTTGA-3′ and 5′-TTCAGCAGCTTGACCACATC-3′, respectively) for murine 
hexokinase 1 (accession number: NM_001146100.1). PCR products were subjected to 1% agarose gel electropho-
resis with ethidium bromide staining (Nacalai Tesque).
Immunostaining. Immunohistochemistry was performed as previously described49. After fixation in 4% 
paraformaldehyde for 1 hour at 4 °C, the eyes were serially dehydrated and frozen in OCT compound (Sakura 
Finetek, Torrance, CA). Cryosections at a thickness of 10 μm underwent staining with IgG from DME sera or 
an anti-hexokinase 1 antibody. After blocking in 10% donkey serum, sections were incubated with serum speci-
mens from DME patients or control subjects (1:100 in 10% donkey serum) or rabbit anti-hexokinase 1 antibody 
(1:100, Cell Signaling Technologies, Beverly, MA) at 4 °C overnight. Goat anti-human IgG secondary antibodies 
conjugated to Cy3 (1:5000, Jackson ImmunoResearch, Westgrove, PA) or anti-rabbit secondary antibodies conju-
gated to Alexa Fluor 488 (1:5000, Life Technologies) were incubated for 1 hour, followed by counterstaining with 
diamidino-2-phenylindole (DAPI).
Paraffin-embedded retinal sections of human adult eyes were obtained from BioChain Institute Inc. (Newark, 
CA). After deparaffinization, the sections were incubated with anti-hexokinase 1 antibody (1:100), followed by 
the secondary antibodies conjugated to Alexa Fluor 594 (1:5000, Life Technologies). Retinal images were obtained 
by fluorescence microscopy (BZ-9000; Keyence, Osaka, Japan).
ELISA. Recombinant human fumarase (1 μg/ml, RayBiotech Inc., Norcross, GA) or recombinant human 
hexokinase 1 (2 μg/ml, ATGen, Gyeonggi-do, Korea) in 100 mM bicarbonate-carbonate buffer (pH 9.6, 100 μl) 
was incubated in a 96-well Nunc Immunoplate Maxisorp plate (Thermo Scientific Inc., Waltham, MA) at 4 °C 
overnight, as described previously33. After blocking (3% bovine serum albumin [BSA] in Tris-buffered saline 
containing 0.1% Tween-20 [TBS-T]), the wells were incubated in serum (1:1000 diluted in 3% BSA in TBS-T) for 
2 hours, followed by horseradish peroxidase (HRP)-labeled anti-human IgG secondary antibodies (1:5000) for 
1 hour, to quantify total levels of anti-hexokinase 1 IgG. The signals detected using 3,3′,5,5′-tetramethylbenzidine 
(TMB; Nacalai Tesque) were measured at an absorption wavelength of 450 nm using an ARVO MX plate reader 
(PerkinElmer, Norwalk, CT). All experiments were performed in duplicate and in a blinded manner, and the 
individual plates were calibrated using two different control serum specimens.
Immunoblot Analysis. SDS-PAGE using the NuPAGE system (Life Technologies) was performed as described 
previously6. Eyeballs from dead pigs were stored on ice soon after slaughter. Isolated porcine retina or recombinant 
human hexokinase 1 was lysed with Laemmli buffer with protease inhibitors. After centrifugation at 15,000 × g for 
5 minutes, supernatants were separated on a gradient gel (4–12%) and transferred to nitrocellulose membranes.
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After the membranes were blocked with 5% milk in TBS-T, they were incubated in the primary anti-
body, i.e., serum specimens from DME patients (1:200) or anti-hexokinase 1 antibody (1:1000), followed by 
HRP-labeled anti-human or anti-rabbit IgG secondary antibodies, respectively (1:5000, Life Technologies). 
Chemiluminescence signals were detected using an enhanced chemiluminescence (ECL) detection system (GE 
Healthcare, Piscataway, NJ).
Immunoprecipitation. Serum IgG was conjugated to protein A-coated beads (rmp Protein A Sepharose 
Fast Flow; GE Healthcare) using a crosslinker (dimethyl pimelimidate [DMP], Thermo Scientific). Porcine retinas 
were lysed with immunoprecipitation buffer (50 mM Tris, pH 7.4, 1% Nonidet-P 40, 10 mM EDTA, 150 mM NaCl 
with protease inhibitors) according to a modification of methods described previously33,50. The lysate was incu-
bated with Protein A beads crosslinked to IgG from DME serum for 2 hours at 4 °C. Immunoprecipitated proteins 
were eluted with 0.1 M glycine (pH 2.0) at 4 °C and subjected to SDS-PAGE as described above.
Mass spectrometry. Proteins in the polyacrylamide gels underwent silver staining using a Pierce Silver Stain 
for Mass Spectrometry Kit (Thermo Scientific). The stained bands were excised and in-gel-digested with trypsin 
using an In-Gel Tryptic Digestion Kit (Thermo Scientific). The tryptic digests were separated using nanoflow 
liquid chromatography (Nano-LC-Ultra 2D-plus equipped with cHiPLC Nanoflex [Eksigent, Dublin, CA, USA]). 
The eluate was directly introduced into a mass spectrometer (TripleTOF 5600+ System coupled to a NanoSpray 
III source and heated interface [AB SCIEX, Framingham, MA]) and ionized in an electrospray ionization-positive 
mode. Data were acquired using an information-dependent acquisition method. The acquired datasets were ana-
lyzed by ProteinPilot software, version 4.5 beta (AB SCIEX), with the NCBI nr database (June 2016).
Statistical analysis. The results are expressed as the mean ± SD. Student’s t-test or one-way ANOVA with 
Bonferroni correction was applied for the parametric populations. The Kruskal-Wallis test with Dunnett’s multi-
ple comparison test or the Mann-Whitney U-test was performed to evaluate the significance of differences in the 
population with nonnormal distributions or unequal variance. Spearman’s rank correlation coefficient was used 
to show statistical correlations. We employed univariate logistic regression analysis using systemic and ocular 
factors and found the significant parameters (Wald’s chi-square > 2), which were used as independent variables 
in the multivariate logistic analysis. The AROC was measured to assess the DR status–discriminating power of 
the serum titer of anti-hexokinase 1 IgG. The AROC is presented as the mean value and 95% CI. These statistical 
analyses were conducted using commercial software (PASW Statistics, version 22; SPSS Inc., Chicago, IL), and 
P < 0.05 was considered significant.
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